An international website dedicated to providing current information on news, reports, publications,and peer-reviewed research articles concerning alcoholism and alcohol-related problems throughout the world. Postings are provided by international contributors who monitor news, publications and research findings in their country, geographical region or program area of interest. All postings are entered without editorial or contributor opinion or comment.
Aims
To support the free and open dissemination of research findings and information on alcoholism and alcohol-related problems. To encourage open access to peer-reviewed articles free for all to view.
For full versions of posted research articles readers are encouraged to email requests for "electronic reprints" (text file, PDF files, FAX copies) to the corresponding or lead author, who is highlighted in the posting.
___________________________________________
For full versions of posted research articles readers are encouraged to email requests for "electronic reprints" (text file, PDF files, FAX copies) to the corresponding or lead author, who is highlighted in the posting.
___________________________________________
Friday, April 16, 2010
CRF-1 Antagonist and CRF-2 Agonist Decrease Binge-Like Ethanol Drinking in C57BL/6J Mice Independent of the HPA Axis
Recent evidence suggests that corticotropin-releasing factor (CRF) receptor (CRFR) signaling is involved in modulating binge-like ethanol consumption in C57BL/6J mice.
In this report, a series of experiments were performed to further characterize the role of CRFR signaling in binge-like ethanol consumption.
The role of central CRFR signaling was assessed with intracerebroventricular (i.c.v.) infusion of the nonselective CRFR antagonist, α-helical CRF9–41 (0, 1, 5, 10 μg/1 μl). The contribution of central CRF type 2 receptor (CRF2R) signaling was assessed with i.c.v. infusion of the selective CRF2R agonist, urocortin (Ucn) 3 (0, 0.05, 0.1, or 0.5 μg/1 μl). The role of the hypothalamic–pituitary–adrenal (HPA) axis was assessed by pretreating mice with intraperitoneal (i.p.) injection of (1) the corticosterone synthesis inhibitor, metyrapone (0, 50, 100, 150 mg/kg) or (2) the glucocorticoid receptor antagonist, mifepristone (0, 25, 50 mg/kg), and (3) by using radioimmunoassay to determine whether binge-like ethanol intake influenced plasma corticosterone levels. Finally, we determined whether the ability of the CRF1R antagonist, CP-154,526 (CP; 0, 10, 15 mg/kg, i.p.), to blunt binge-like drinking required normal HPA axis signaling by comparing the effectiveness of CP in adrenalectomized (ADX) and normal mice.
Results showed that i.c.v. infusion of a 1 μg dose of α-helical CRF9–41 significantly attenuated binge-like ethanol consumption relative to vehicle treatment, and i.c.v. infusion of Ucn 3 dose-dependently blunted binge-like drinking.
On the other hand, metyrapone nonselectively reduced both ethanol and sucrose consumption, mifepristone did not alter ethanol drinking, and binge-like drinking did not correlate with plasma corticosterone levels.
Finally, i.p. injection of CP significantly attenuated binge-like ethanol intake in both ADX and normal mice.
Together, these results suggest that binge-like ethanol intake in C57BL/6J mice is modulated by CRF1R and CRF2R signaling, such that blockade of CRF1R or activation of CRF2R effectively reduces excessive ethanol intake.
Furthermore, normal HPA axis signaling is not necessary to achieve binge-like drinking behavior.
Read Full Abstract
Request Reprint E-Mail: thiele@unc.edu
_______________________________________